


Searching News Database: Teijin Pharma
HSMN NewsFeed - 1 Aug 2019
Neuronetics(R) Announces First TMS Patient Treated Under New Japan Reimbursement Policy
Neuronetics(R) Announces First TMS Patient Treated Under New Japan Reimbursement Policy
HSMN NewsFeed - 28 Apr 2017
Teijin to Withdraw from U.S. Home Health Care Business to Complete Business Restructuring
Teijin to Withdraw from U.S. Home Health Care Business to Complete Business Restructuring
HSMN NewsFeed - 14 Feb 2009
FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
HSMN NewsFeed - 5 May 2008
Ipsen: Adenuric(R) (Febuxostat) Receives Marketing Authorisation in the European Union
Ipsen: Adenuric(R) (Febuxostat) Receives Marketing Authorisation in the European Union
HSMN NewsFeed - 2 Oct 2006
Ipsen: EMEA's Validation of Febuxostat's Marketing Authorization Application in the European Union
Ipsen: EMEA's Validation of Febuxostat's Marketing Authorization Application in the European Union
Additional items found! 1
Members Archive contains
1 additional stories matching:
Teijin Pharma
(Password required)
Teijin Pharma
(Password required)
